Clinical effects of empagliflozin dose increase in patients with type 2 diabetes: a retrospective observational study
Not Applicable
- Conditions
- Type 2 diabetes
- Registration Number
- JPRN-UMIN000041543
- Lead Sponsor
- Department of Metabolic Medicine, Nishinihon Hospital
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Pending
- Sex
- All
- Target Recruitment
- 100
Inclusion Criteria
Not provided
Exclusion Criteria
The exclusion criteria for the subjects are as follow. 1. Subjects with acute and/or chronic inflammation 2. Subjects with fresh cardiovascular and/or cerebrovascular diseases 3. Subjects with liver cirrhosis. 4. Subjects with severe respiratory disease or severe heart failure 5. Subjects with alcoholicsm or medicinal intoxication 6. Subjects with psychosis 7. Subjects who doctors judge as unfitness
Study & Design
- Study Type
- Observational
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Comparing the change in HbA1c between before and after dose-increasing of empagliflozin.
- Secondary Outcome Measures
Name Time Method